--- title: "10:34 ET\n\t\t\t\n\t\t\t\n\t\t\t\tKuehn Law Encourages Investors of Dick's Sporting Goods, Inc. to Contact Law Firm" description: "Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Dick's Sporting Goods, Inc. (NYSE: DKS). A federal securities lawsuit claims that insiders misrepre" type: "news" locale: "en" url: "https://longbridge.com/en/news/253242786.md" published_at: "2025-08-15T14:34:48.000Z" --- # 10:34 ET Kuehn Law Encourages Investors of Dick's Sporting Goods, Inc. to Contact Law Firm > Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Dick's Sporting Goods, Inc. (NYSE: DKS). A federal securities lawsuit claims that insiders misrepresented the demand for products in the Outdoor segment, leading to excess inventory and negatively impacting profitability. Shareholders who purchased DKS shares before May 25, 2022, are encouraged to contact Kuehn Law for potential legal action, as there may be limited time to enforce their rights. Kuehn Law covers all case costs for its clients. , /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of **Dick's Sporting Goods, Inc. (NYSE: DKS)** breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Dick's Sporting Goods caused the company to misrepresent or fail to disclose that (i) demand for products in DKS's Outdoor segment was slowing faster than represented, resulting in excess inventory; (ii) the "structural changes" that were repeatedly touted, including differentiated products, improved pricing technology, and more efficient clearance channels, did not allow the Company to manage its excess inventory without hurting the Company's profitability; (iii) the need to liquidate excess inventory, including in the Outdoor segment, would have a materially negative effect on the Company's profitability; and (iv) as a result of the above, statements about DKS's business condition and prospects were materially false and misleading If you currently own DKS **and purchased prior to May 25, 2022** please contact Justin Kuehn, Esq. here, by email at \[email protected\] or call (833) 672-0814. **Kuehn Law pays all case costs and does not charge its investor clients.** *Shareholders should contact the firm immediately as there may be limited time to enforce your rights.* **Why Your Participation Matters:** As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. *Your investment. Your voice. Your future.*™ For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts: Kuehn Law, PLLC Justin Kuehn, Esq. 53 Hill Street, Suite 605 Southampton, NY 11968 \[email protected\] (833) 672-0814 SOURCE Kuehn Law, PLLC ### Related Stocks - [DKS.US - Dick's Sporting Goods](https://longbridge.com/en/quote/DKS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | OpenClaw 之父爆猛料：Meta 和 OpenAI 跪着搶人，小扎親自求收購 | 在一場重磅播客訪談中，OpenClaw 之父 Peter Steinberger 透露，Meta 的扎克伯格和 OpenAI 的 Sam Altman 都在積極拉攏他，甚至扎克伯格親自表示對 OpenClaw 的讚賞。兩大科技巨頭同時爭搶人 | [Link](https://longbridge.com/en/news/275962731.md) | | 耐克公司將股息上調 2.5%，達到每股 0.41 美元 | 耐克公司將股息提高 2.5%，至每股 0.41 美元 | [Link](https://longbridge.com/en/news/275967528.md) | | Assetmark Inc.增加了對碧迪醫療公司（Becton, Dickinson and Company）的持股 $BDX | Assetmark Inc. 在第三季度將其在碧迪醫療（NYSE:BDX）的持股增加了 49.5%，目前擁有 225,967 股，價值 4229 萬美元。其他機構投資者也調整了他們的持股，Brighton Jones LLC 將其持股增加了 | [Link](https://longbridge.com/en/news/275971326.md) | | 根據最近的 SEC 文件，萊迪思半導體的一位內部人士出售了價值 498,527 美元的股份 | 東部時間 2026 年 2 月 13 日下午 3:48（MT Newswires）-- Pravin Desale，研發高級副總裁，於 2026 年 2 月 12 日出售了 4,937 股萊迪思半導體（LSCC），交易金額為 498,527 | [Link](https://longbridge.com/en/news/275944601.md) | | Advanced Biomed Inc.的 SEC 10-Q 報告 | Advanced Biomed Inc. 發佈了其 SEC Form 10-Q 報告，展示了顯著的財務收益，包括 686 萬美元的淨收入。報告強調了公司在腫瘤學產品方面的創新和監管進展，並計劃在北美和歐洲擴展市場。關鍵進展包括最近剝離其香港 | [Link](https://longbridge.com/en/news/275947350.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.